Product Description
Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22339187/)
Mechanisms of Action: NEU Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Canada | European Medicines Agency | Germany | Hungary | Ireland | Italy | Japan | Korea | Lithuania | Poland | Portugal | Sweden | Taiwan | United States
Approved Indications: Influenza, Human
Known Adverse Events: Diarrhea
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Influenza, Human
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20131182 | P3 |
Recruiting |
Influenza, Human |
None |
|
| CTR20131184 | P3 |
Recruiting |
Influenza, Human |
None |